全球分子影像市場

到 2030 年，全球分子影像市場規模將達到 104 億美元

全球分子影像市場規模預計在2024年為86億美元，到2030年將達到104億美元，2024年至2030年的複合年成長率為3.3%。單光子發射電腦斷層掃描（SPC）是本報告分析的細分市場之一，預計其複合年成長率為3.3%，到分析期結束時規模將達到46億美元。正子斷層掃描（PET）細分市場在分析期間的複合年成長率預計為4.1%。

美國市場預計將達到 23 億美元，中國市場複合年成長率將達到 6.1%

美國分子影像市場規模預計在2024年達到23億美元。作為世界第二大經濟體，中國預計2030年市場規模將達到21億美元，在分析期間（2024-2030年）的複合年成長率為6.1%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為1.3%和2.5%。在歐洲，預計德國的複合年成長率為1.9%。

全球分子影像市場—主要趨勢與促進因素摘要

分子影像如何徹底改變精準醫療和早期疾病檢測？

分子成像已成為現代醫療保健的基礎技術，為在分子和細胞層面上洞察生物過程提供了前所未有的視角。與主要關注解剖結構的傳統影像技術不同，分子影像提供功能和代謝訊息，有助於早期疾病檢測、分期和個人化治療計劃。癌症、心血管疾病和神經退化性疾病等慢性疾病的增加推動了對更精確診斷工具的需求。正子斷層掃描 (PET)、單光子發射電腦斷層掃描 (SPECT) 以及 PET-CT 和 PET-MRI 等混合成像技術透過即時追蹤病情進展和治療反應，改變了診斷工作流程。放射性藥物作為標靶成像的生物標記日益整合，進一步提高了診斷準確性和患者預後。隨著對非侵入性早期檢測方法的需求不斷成長，分子影像繼續被醫院、研究機構和製藥行業廣泛採用，在精準醫療中發揮關鍵作用。

哪些技術進步推動了分子影像市場的發展？

由於顯像模式、人工智慧 (AI) 和放射性藥物的不斷進步，分子成像市場正在迅速轉型。人工智慧驅動的影像分析能夠更快、更準確地解讀複雜的影像數據，減少診斷錯誤並改善臨床決策。此外，針對特定生物標記的新型放射性藥物的開發顯著提高了分子成像技術的靈敏度和特異性。 PET-CT 和 SPECT-CT 等混合影像系統透過在單次掃描中提供整合的功能和解剖學訊息，進一步完善了診斷領域，提高了效率和患者舒適度。光學和螢光分子成像的興起擴展了其在腫瘤學和神經病學中的應用，使研究人員能夠即時觀察分子活動。此外，微型化和攜帶式分子成像設備正在開發中，以促進照護現場診斷，尤其是在資源有限的環境中。隨著技術的不斷發展，人工智慧、機器學習和下一代影像劑的整合有望重新定義分子影像市場，並為疾病管理和治療最佳化帶來新的可能性。

監管和市場動態如何影響分子影像的採用？

法律規範和市場動態在塑造分子成像領域的發展中發揮關鍵作用。嚴格的放射性藥物和成像設備核准和分銷指南要求持續創新以滿足安全性和有效性標準。美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等機構實施了嚴格的合規措施，以確保分子成像技術的可靠和道德的使用。同時，政府、醫療機構和私人實體不斷增加的投資正在推動該領域的舉措。官民合作關係趨勢正在促進新興國家分子影像基礎設施的擴張，拓寬先進診斷服務的可近性。此外，診斷影像的報銷政策對市場採用率有顯著影響，而優惠的報銷模式則鼓勵更廣泛的臨床應用。此外，製藥業在藥物開發和臨床試驗中依賴分子成像，這增強了該領域的市場發展潛力。隨著監管格局的不斷發展，將創新與合規相結合對於維持市場成長和擴大分子成像解決方案的可及性至關重要。

推動分子成像市場成長的關鍵因素有哪些？

全球分子影像市場的成長受到多種因素的推動，包括疾病負擔的增加、技術進步、監管支持和研究投入的增加。癌症、心血管疾病和神經系統疾病發病率的上升推動了對早期準確診斷的需求，使分子影像成為現代醫療保健的關鍵工具。放射性藥物、基於人工智慧的影像分析和混合成像系統的創新顯著提高了診斷的準確性，使其在醫療和研究應用中得到廣泛應用。個人化醫療和標靶治療方法的擴展也刺激了對分子影像的需求，因為它們可以根據個別患者情況制定個人化的治療策略。此外，新興國家醫療成本的上漲和成像基礎設施的擴大，正在推動市場向服務欠缺地區滲透。製藥和生物技術產業依賴分子影像進行藥物發現、生物標記檢驗和臨床試驗監測，這也是主要的成長動力。此外，非侵入性成像技術和下一代示蹤劑的進步有望擴大分子影像的應用範圍。隨著全球醫療保健系統優先考慮早期疾病檢測和精準醫療，分子影像市場預計將持續擴張，為行業相關人員和研究人員提供新的機會。

部分

模式（單光子發射電腦斷層掃描模式、正子斷層掃描模式、核磁共振超音波成像模式、其他模式）、應用（腫瘤學應用、心血管應用、神經學應用、呼吸系統應用、其他應用）、最終用途（醫院最終用途、診斷成像中心最終用途、研究最終用途）

受訪公司範例

• Abbott Laboratories
• Bio-Rad Laboratories
• Bruker Corporation
• Canon Medical Systems Corporation
• Cubresa Inc.
• Esaote
• GE HealthCare
• Koninklijke Philips NV
• Mediso
• PerkinElmer
• PerkinElmer Inc.
• Positron Corporation
• QIAGEN
• Roche Diagnostics
• Shimadzu Corporation
• Siemens AG
• Siemens Healthineers
• Thermo Fisher Scientific
• United Imaging Healthcare Co.

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 沒有遵循查詢 LLM 或特定產業SLM 的典型規範，而是建立了一個來自世界各地專家的精選內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地以及進出口情況（成品和原始OEM）預測其競爭地位的變化。這種複雜多變的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 競賽

Global Molecular Imaging Market to Reach US$10.4 Billion by 2030

The global market for Molecular Imaging estimated at US$8.6 Billion in the year 2024, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Single Photon Emission Computed Tomography Modality, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the Positron Emission Tomography Modality segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 6.1% CAGR

The Molecular Imaging market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Molecular Imaging Market - Key Trends & Drivers Summarized

How Is Molecular Imaging Revolutionizing Precision Medicine and Early Disease Detection?

Molecular imaging has emerged as a cornerstone technology in modern healthcare, offering unparalleled insights into biological processes at the molecular and cellular levels. Unlike traditional imaging modalities that primarily focus on anatomical structures, molecular imaging provides functional and metabolic information that aids in early disease detection, staging, and personalized treatment planning. The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions has intensified the need for more precise diagnostic tools. Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and hybrid imaging techniques such as PET-CT and PET-MRI have transformed diagnostic workflows by enabling real-time tracking of disease progression and treatment response. The growing integration of radiopharmaceuticals, which serve as biomarkers for targeted imaging, is further enhancing diagnostic accuracy and patient outcomes. As the demand for non-invasive and early detection methods rises, molecular imaging continues to gain widespread adoption across hospitals, research institutions, and pharmaceutical industries, reinforcing its pivotal role in precision medicine.

What Technological Advancements Are Driving the Molecular Imaging Market?

The molecular imaging market is witnessing a rapid transformation, driven by continuous advancements in imaging modalities, artificial intelligence (AI), and radiopharmaceuticals. AI-powered imaging analytics have enabled faster and more precise interpretation of complex imaging data, reducing diagnostic errors and improving clinical decision-making. Additionally, the development of novel radiotracers targeting specific biomarkers has significantly enhanced the sensitivity and specificity of molecular imaging techniques. Hybrid imaging systems, such as PET-CT and SPECT-CT, have further refined the diagnostic landscape by providing integrated functional and anatomical insights in a single scan, thereby improving efficiency and patient comfort. The rise of optical and fluorescence-based molecular imaging is expanding applications in oncology and neurology, enabling researchers to visualize molecular activity in real-time. Moreover, miniaturized and portable molecular imaging devices are being developed to facilitate point-of-care diagnostics, particularly in resource-limited settings. As technology continues to evolve, the convergence of AI, machine learning, and next-generation imaging agents is expected to redefine the molecular imaging market, unlocking new possibilities for disease management and treatment optimization.

How Is Regulatory and Market Dynamics Influencing Molecular Imaging Adoption?

Regulatory frameworks and market dynamics play a crucial role in shaping the growth of the molecular imaging sector. Stringent guidelines governing the approval and distribution of radiopharmaceuticals and imaging devices necessitate continuous innovation to meet safety and efficacy standards. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have imposed rigorous compliance measures to ensure the reliability and ethical use of molecular imaging technologies. At the same time, increasing investments from governments, healthcare institutions, and private entities are driving research and development initiatives in this space. The growing trend of public-private partnerships is facilitating the expansion of molecular imaging infrastructure in emerging economies, broadening access to advanced diagnostic services. Additionally, reimbursement policies for imaging procedures significantly impact market adoption, with favorable reimbursement models encouraging wider clinical utilization. Furthermore, the pharmaceutical industry's reliance on molecular imaging for drug development and clinical trials is reinforcing the sector’s market potential. As regulatory landscapes continue to evolve, aligning innovation with compliance will be essential in sustaining market growth and expanding the accessibility of molecular imaging solutions.

What Are the Key Factors Fueling the Growth of the Molecular Imaging Market?

The growth in the global molecular imaging market is driven by several factors, including rising disease burden, technological advancements, regulatory support, and increasing research investments. The growing incidence of cancer, cardiovascular diseases, and neurological disorders has amplified the need for early and accurate diagnosis, positioning molecular imaging as a critical tool in modern healthcare. Innovations in radiopharmaceuticals, AI-driven imaging analytics, and hybrid imaging systems have significantly enhanced diagnostic precision, leading to wider adoption across medical and research applications. The expansion of personalized medicine and targeted therapy approaches is also boosting demand for molecular imaging, as it enables tailored treatment strategies based on individual patient profiles. Additionally, increasing healthcare expenditures in emerging economies and the expansion of imaging infrastructure are driving market penetration in underserved regions. The pharmaceutical and biotechnology industries' dependence on molecular imaging for drug discovery, biomarker validation, and clinical trial monitoring is another key growth accelerator. Moreover, ongoing research into non-invasive imaging techniques and next-generation tracers is expected to expand the scope of molecular imaging applications. As healthcare systems worldwide prioritize early disease detection and precision medicine, the molecular imaging market is poised for sustained expansion, offering new opportunities for industry stakeholders and researchers alike.

SCOPE OF STUDY:

The report analyzes the Molecular Imaging market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Modality (Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality, Other Modalities); Application (Oncology Application, Cardiovascular Application, Neurology Application, Respiratory Application, Other Applications); End-Use (Hospitals End-Use, Diagnostic Imaging Centers End-Use, Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Abbott Laboratories
• Bio-Rad Laboratories
• Bruker Corporation
• Canon Medical Systems Corporation
• Cubresa Inc.
• Esaote
• GE HealthCare
• Koninklijke Philips N.V.
• Mediso
• PerkinElmer
• PerkinElmer Inc.
• Positron Corporation
• QIAGEN
• Roche Diagnostics
• Shimadzu Corporation
• Siemens AG
• Siemens Healthineers
• Thermo Fisher Scientific
• United Imaging Healthcare Co.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Molecular Imaging - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Chronic Diseases Accelerates Demand for Advanced Molecular Imaging Techniques
  • Advancements in Nuclear Medicine Fuel Growth in PET and SPECT Imaging Modalities
  • Growing Focus on Personalized Medicine Expands Market Opportunities for Targeted Molecular Imaging
  • Surge in Oncology Research and Clinical Trials Boosts Adoption of Molecular Imaging in Cancer Detection
  • Technological Innovations in Imaging Agents Enhance the Accuracy and Efficiency of Molecular Imaging Procedures
  • Increasing Demand for Non-invasive Diagnostic Techniques Drives Adoption of Molecular Imaging in Healthcare
  • Growing Aging Population Spurs Demand for Early Disease Detection and Monitoring Solutions
  • Rising Popularity of Biomarker Discovery and Development Fuels Demand for Molecular Imaging Technologies
  • Integration of Artificial Intelligence and Machine Learning into Molecular Imaging Systems Enhances Diagnostic Capabilities
  • Expansion of Healthcare Infrastructure in Emerging Markets Expands Addressable Market Opportunity for Molecular Imaging
  • Growing Focus on Early Disease Detection Strengthens Business Case for Molecular Imaging Technologies
  • Regulatory Advancements in the Approval of Novel Imaging Agents Propel Growth in the Molecular Imaging Market
  • Government Initiatives and Funding for Medical Research Drive Innovation in Molecular Imaging Techniques
  • Development of Radiopharmaceuticals and Novel Imaging Probes Opens New Avenues for Molecular Imaging Applications
  • Increasing Collaboration Between Biopharmaceutical Companies and Imaging Device Manufacturers Spurs Market Growth
  • Rising Healthcare Expenditure and Investment in Diagnostic Imaging Systems Support Demand for Molecular Imaging Solutions
  • Growing Interest in Cardiovascular Disease Management Drives Adoption of Molecular Imaging for Early Diagnosis and Risk Assessment
  • Integration of Molecular Imaging with Theranostics Strengthens Adoption of Personalized Treatment Plans
  • Pressure to Improve Healthcare Outcomes and Reduce Costs Promotes the Use of Advanced Imaging in Healthcare Facilities
  • Increasing Use of Molecular Imaging in Preclinical Studies Accelerates Demand for Imaging Solutions in Research and Development
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Molecular Imaging Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Molecular Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Molecular Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Molecular Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Single Photon Emission Computed Tomography Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Single Photon Emission Computed Tomography Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Positron Emission Tomography Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Positron Emission Tomography Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Positron Emission Tomography Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Nuclear Magnetic Resonance Spectrometer Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Nuclear Magnetic Resonance Spectrometer Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Nuclear Magnetic Resonance Spectrometer Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Molecular Ultrasound Imaging Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Molecular Ultrasound Imaging Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Molecular Ultrasound Imaging Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Modalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Cardiovascular Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Neurology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Respiratory Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Respiratory Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Respiratory Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Diagnostic Imaging Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Diagnostic Imaging Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Diagnostic Imaging Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• JAPAN
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• CHINA
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 71: China Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• EUROPE
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Molecular Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Molecular Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Molecular Imaging by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• FRANCE
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 92: France Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• GERMANY
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 119: UK Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Molecular Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Molecular Imaging by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• INDIA
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 176: India Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Molecular Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Molecular Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Molecular Imaging by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Molecular Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Molecular Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Molecular Imaging by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• AFRICA
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION